Lyka Labs (BOM:500259) ROCE %: -26.14% (As of Mar. 2026)


BOM:500259 Lyka Labs Ltd BOM:500259
49 GF Score
Price ₹72.00
GF Value ₹127.10
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lyka Labs ROCE %?

Lyka Labs BOM:500259 -2.98% 49 ROCE % is -26.14% as of Mar. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 49/100 and a GF Value™ of ₹127.10 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lyka Labs's annualized ROCE % for the quarter that ended in Mar. 2026 was -26.14%.

Lyka Labs  (BOM:500259) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lyka Labs ROCE % Related Terms

Lyka Labs ROCE % Historical Data

* Premium members only.

The historical data trend for Lyka Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyka Labs ROCE % Chart

Lyka Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.12 -1.41 3.16 10.78 -6.89

Lyka Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.76 6.81 -11.52 2.10 -26.14
BOM:500259
49GF Score
Lyka Labs Ltd BOM:500259
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyka Labs ROCE % Calculation

Lyka Labs's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-86.19/( ( (1762.06 - 466.312) + (1745.364 - 538.992) )/ 2 )
=-86.19/( (1295.748+1206.372)/ 2 )
=-86.19/1251.06
=-6.89 %

Lyka Labs's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-315.388/( ( (0 - 0) + (1745.364 - 538.992) )/ 1 )
=-315.388/( ( 0 + 1206.372 )/ 1 )
=-315.388/1206.372
=-26.14 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -26.14% mean?
Lyka Labs (BOM:500259) has a ROCE % of -26.14% as of Mar. 2026.
Is Lyka Labs' ROCE % too high?
Lyka Labs' current ROCE % is -26.14%. Overall, Lyka Labs has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' ROCE % compare to VRTX and REGN?
Lyka Labs' ROCE % of -26.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Lyka Labs's current ROCE % is -26.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.10, compared to a current price of ₹72.00 — trading 43.4% below its estimated fair value. The current ROCE % is -26.14%. Lyka Labs' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current ROCE % is -26.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹72.00 is trading 43.4% below its estimated GF Value™ of ₹127.10. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • ROCE %: -26.14%
  • GF Value™: ₹127.10 vs. price of ₹72.00 (43.4% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
49GF Score

Get the complete analysis for BOM:500259

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹72.00
Price
₹127.10
GF Value